Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in th
Biosimilar competition to AbbVie’s cash-cow product Humira ramped up in the first quarter, but more worrying for the company was disappointing growth among the products it
AbbVie's would-be blockbuster Rinvoq has notched up another positive trial in Crohn's disease, showing that it can achieve clinical remission over a full year when used as a maintenance the